|
⚲
|
| Keyboard |
| First Turn Management LLC
✚
|
|
|---|---|
| CRD # | 327421 |
| SEC # | 801-128649 |
| CIK # | 0001993440 |
| AUM | 900.1 M (2026-03-25) |
| Employees | 4 (100% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 310-902-0958 |
| Address | 674 Via de La Valle Solana Beach, CA 92075 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/25/2026) [Brochure] |
|---|
Item 5: Fees and Compensation First Turn is a fee-only investment management firm. First Turn bases its investment management US-DOCS\143229937.17 4 fees on a percentage of assets under management and/or the performance of the account. First Turn reserves the right to negotiate fees and alternative minimum account sizes on a case-by- case basis for separately managed accounts. First Turn may agree to aggregate assets for related accounts for fee calculations. First Turn, in its sole discretion, may also waive its fee and/or charge a lesser investment advisory fee based upon various criteria (e.g., historical relationship, type of assets, account complexity, anticipated future asset growth, dollar amounts of assets to be managed, related accounts, account composition, negotiations with clients, investment vehicle, “most favored nation” agreements, etc.). Management Fees and Performance Allocation Payable by the Funds The investment management fees received by First Turn for managing the private Funds are described in the Fund’s Governing Documents. The fees are calculated by the Fund’s administrator and deducted by First Turn as outlined in the Fund’s Governing Documents. The fee schedule for the Funds is set forth in Item 6 below. Fund Expenses The Funds bears the costs and expenses incidental to its organization and ongoing operation, including, without limitation, (a) all trading costs and expenses (such as, for example, brokerage commissions and charges, expenses relating to short sales, clearing and settlement charges, option premiums and custodial and service fees), (b) all interest and commitment fees on loans and debit balances (on margin or otherwise), (c) the costs and expenses of negotiating and entering into contracts and arrangements and making investments in the ordinary course of the Fund’s activities (such as brokerage, legal, accounting and other professional and consulting fees and expenses arising from particular investments and potential investments) and similar expenses in terminating those contracts and arrangements and disposing of the Fund’s investments, (d) all costs and expenses incurred in visiting companies and attending research conferences (for example, airfare, hotel accommodations and meals), (e) all costs and expenses associated with registering the Fund’s restricted securities (if any), (f) all costs and expenses incurred in attempting to protect or enhance the value of the Fund’s investments (including the costs of instituting and defending lawsuits), (g) all income taxes, withholding taxes, transfer taxes and other governmental charges and duties, (h) all fees and charges of custodians, clearing agencies and banks, (i) all administration, bookkeeping, recordkeeping, legal, accounting, auditing, tax preparation and all professional, expert and consulting fees and expenses arising in connection with the Fund’s activities (including fees and expenses of counsel for the Funds, the Fund’s general partner or one or more officers or managers of the Fund’s general partner, service contracts related to on-line research, portfolio management and quotation services and equipment (including computer hardware and software related thereto) and all fees, costs and expenses of accounting, bookkeeping and recordkeeping services of the funds administrator or any similar service provider retained by the Fund’s general partner to assist it in performing these services for the Funds, (j) all fees, costs and expenses of offering and selling Interests and communicating with investors (including, without limitation, legal and accounting fees and expenses, governmental and self-regulatory agency filing fees, and travel expenses, such as airfare, hotel accommodations and meals), (k) all premiums and other costs and expenses of insurance policies as the general partner of the Funds considers appropriate, insuring the Funds, the general partner of the Funds and their affiliates against liabilities that may arise in connection with the business or management of the Funds, (l) all costs and expenses of proxy voting services, (m) any contingencies for which the general partner determines reserves are required, and (n) any US-DOCS\143229937.17 5 extraordinary expenses (such as litigation expenses). Except as described above, the general partner of the Funds shall bear all of its operating, general, administrative and overhead costs and expenses and shall not otherwise charge the Funds for any thereof, except that these costs and expenses, together with all or any portion of the Fund’s expenses, may be paid by securities brokerage firms and futures commission merchants to which the general partner of the Funds directs the securities trades of the Funds and any other accounts managed by the general partner of the Funds. Any expense of the Funds that relates specifically to “Special Securities,” as defined in the Fund’s Governing Documents, will be charged solely against the investors in the Funds participating in such Special Securities in proportion to their interest in such Special Securities. The Firm will determine, in its sole discretion, whether an expense relates specifically to Special Securities (including the determination that an expense will not be specifically allocated for purposes of administrative convenience or otherwise). The Fund’s Governing Documents permit an investor to, on at least 30 days’ advance notice to First Turn and subject to certain restrictions as provided in the Fund’s Governing Documents, withdraw all or part of its capital account balance (except for any portion of the capital account balance attributable to certain allocations of Special Securities) and any amount attributable to the audit hold ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/25/2026) [Brochure] |
|---|
Item 7: Types of Clients First Turn provides investment advisory services to two private funds and/or separately managed accounts as described in Item 4. Private Funds First Turn will impose a minimum subscription amount of $1 million to invest in the Funds. The details regarding minimum account sizes, fees and other important information are outlined in each client’s Governing Documents. First Turn reserves the right to waive account minimums at its sole discretion. Separate Accounts The institutional account minimum size is $25 million. Separate account client minimums may be individually negotiated. First Turn reserves the right to waive account minimums at its sole discretion. Other Services First Turn provides healthcare research services exclusively to Nicholas Investment Partners (“Nicholas”), a long-only equity manager, pursuant to the terms of the Services Agreement (as defined below), for a fixed annual fee. Under the Services Agreement, Nicholas has access to the First Turn investment team and their research library and has daily transparency into First Turn’s investment portfolio. Nicholas, at its sole discretion, may choose to purchase or sell these securities in their own client portfolios, which are unrelated to First Turn or its clients. This arrangement gives rise to conflicts of interest related to front running, liquidity, market timing, and the price of execution for certain transactions, where either Nicholas or First Turn will have an incentive to favor themselves or certain clients to the detriment of other clients. Nicholas and First Turn have created policies and controls to address these conflicts of interest. Please see item 12 for further detail. |
| CIK | Period |
|---|---|
| 0001993440 |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| United Therapeutics Corp | 62.1 | ||
| Abivax Sa | 51.9 | ||
| Bridgebio Pharma Inc | 51.7 | ||
| Xenon Pharmaceuticals Inc | 45.8 | ||
| Revolution Medicines Inc | 45.5 | ||
| Apogee Therapeutics Inc | 43.2 | ||
| Insmed Inc | 40.6 | ||
| Nuvalent Inc | 37.9 | ||
| Mirum Pharmaceuticals Inc | 37.0 | ||
| UNUM Therapeutics Inc | 36.5 | ||
| Roivant Sciences Ltd | 33.0 | ||
| Axsome Therapeutics Inc | 31.9 | ||
| IDEAYA Biosciences Inc | 29.1 | ||
| Oric Pharmaceuticals Inc | 25.6 | ||
| Imara Inc | 24.5 | ||
| Celcuity Inc | 24.0 | ||
| Scholar Rock Holding Corp | 21.9 | ||
| Kymera Therapeutics Inc | 21.2 | ||
| Cytokinetics Inc | 18.7 | ||
| Magenta Therapeutics Inc | 18.5 | ||
| Marika Inc | 18.5 | ||
| Newamsterdam Pharma Co NV | 17.9 | ||
| Signal Genetics Inc | 17.8 | ||
| Ascendis Pharma A/S | 17.5 | ||
| Fulcrum Therapeutics Inc | 17.3 | ||
| Vera Therapeutics Inc | 17.0 | ||
| Natera Inc | 16.2 | ||
| Erasca Inc | 14.0 | ||
| Praxis Precision Medicines Inc | 13.7 | ||
| Prev | Page 1 | Next | |||
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | First Turn RX LP | [2025-04-17] | 1.5 M | 2.5 M |
| Filed 2025-04-15 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | First Turn LP | [2023-11-16] | 148.6 M | 33.8 M |
| Filed 2025-11-06 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 93.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 1 | 807.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 4 | 900.1 |
| By Discretionary | ||
| Discretionary | 4 | 900.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 4 | 900.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 807.0 | |
| United States Persons | 93.1 | |
| Total | 4 | 900.1 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| John Wylie | Executive Officer | 12 | 3 | |
| Catherine Nicholas | Executive Officer | 7 | 3 | |
| Nicholas Investment Partners LP | Executive Officer | 7 | 3 | |
| Christopher Siriani | Executive Officer | 5 | 3 | |
| Christopher Sirani | Executive Officer | 4 | 3 | |
| Nicholas Investment Partners LLC | Executive Officer | 4 | 3 | |
| Lisa Wheatley | Executive Officer | 3 | 2 | |
| First Turn RX GP LLC | Executive Officer | 1 | 1 | |
| Meredith Genova | Director | 1 | 1 | |
| Laura Demarco | Director | 1 | 1 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001993440] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional, Retail |
| Fund Types | Hedge Fund |
| Comparable Firms | State | AUM |
|---|---|---|
|
Buoyant Capital Private Limited
✚
|
924.8 M | |
|
PCJ Investment Counsel Ltd
✚
|
924.3 M | |
|
Old West Investment Management LLC
✚
|
CA | 915.7 M |
|
Formidable Asset Management LLC
✚
|
OH | 903.0 M |
|
Maytech Global Investments LLC
✚
|
NY | 895.1 M |
|
Optima Asset Management LLC
✚
|
NY | 891.6 M |
|
Thomas J Herzfeld Advisors Inc
✚
|
FL | 890.4 M |
|
Tran Capital Management LP
✚
|
CA | 890.3 M |
|
Martin Investment Management LLC
✚
|
FL | 888.1 M |
|
Bayshore Capital Advisors LLC
✚
|
FL | 879.2 M |